Compare Amylx Pharmaceuticals Inc (AMLX) vs Hershey Co (HSY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amylx Pharmaceuticals Inc vs Hershey Co — how do they compare? Amylx Pharmaceuticals Inc trades at $17.28 (market cap $1.98B), while Hershey Co trades at $176.74 (market cap $35.23B). The key difference: Hershey Co is far larger — about 17.8× Amylx Pharmaceuticals Inc's market cap, and Hershey Co pays a 3.34% dividend while Amylx Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMLX | HSY | |
|---|---|---|
Market Cap | $1.98B | $35.23B |
Sector | Health | Consumer Staples |
52-Week High | $18.70 | $236.28 |
52-Week Low | $7.64 | $162.31 |
Enterprise Value | $1.70B | $40.03B |
Dividend Yield | — | 3.34% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMLX trades at $17.77, down 3.32% today, with a bullish technical signal from moving averages and strong analyst support. The company is in a pivotal phase with key Phase 3 data for avexitide expected in Q3 2026, targeting a potential 2027 launch. Financially, it shows significant losses with negative ROE and ROA, but cash flow from financing activities provides runway. Recent news highlights clinical progress and conference presentations, alongside ongoing class action settlement discussions.
The outlook hinges on successful clinical trial outcomes, particularly avexitide's Phase 3 readout, which could drive substantial upside toward the $30.50 consensus price target. However, high execution risk, persistent cash burn, and legal overhangs pose threats to near-term stability. Investor sentiment remains cautiously optimistic given the 90.9% buy rating from analysts, but the stock is speculative until profitability milestones are achieved.
HSY trades at $173.66, up 1.17% with recent earnings beats and easing cocoa costs supporting fundamentals. Technicals are bearish with resistance at $175, while valuation metrics like a P/E of 32.34 suggest premium pricing. The company maintains strong cash flow and a 3.22% dividend yield, with Q2 2026 earnings due July 30, 2026, as a key catalyst.
Outlook: Upside exists to the $210.33 consensus target if margin recovery continues, but high debt and volatile input costs pose risks. Analyst sentiment is cautious with 65.7% hold ratings, reflecting balanced growth and valuation concerns amid competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amylx Pharmaceuticals Inc
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →About Hershey Co
Hershey is a leading confectionery manufacturer in the U.S. (around a $25 billion market), controlling around 46% of the domestic chocolate space (per IRI). Beyond its namesake label, the firm's mix has expanded over the last 85 years and now consists of 100 brands, including Reese's, Kit Kat, Kisses, and Ice Breakers. Hershey's products are sold in about 80 countries, albeit with just a high-single-digit percentage of sales coming from markets outside the U.S., including Brazil, India, and Mexico. The firm has sought inorganic opportunities to extend its reach beyond its core confection business, adding Amplify Snack Brands and its Skinny Pop ready-to-eat popcorn to its mix and Pirate Brands (including the Pirate's Booty, Smart Puffs, and Original Tings brands) over the past few years.
Read more on HSY →
